Black Diamond Therapeutics, Inc. SEC filings BDTX
Black Diamond Therapeutics, Inc. has 485 filings in SEC EDGAR's recent list, going back to Mar 28, 2017. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 26, 2026 |
| DEFA14A | Additional proxy material | Apr 18, 2025 | — |
| DEF 14A | Proxy statement | Apr 18, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 6, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2024 | Jun 6, 2024 |
| DEFA14A | Additional proxy material | Apr 4, 2023 | — |
| DEF 14A | Proxy statement | Apr 4, 2023 | May 16, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 18, 2021 |
Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BDTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1701541
- Former names
- Aset Therapeutics, Inc. (until Jan 4, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.